OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
93
Results
Show all
Save search
Copy query
Show results for
Unknown
(93)
Publication Date
Release Date
2021
(19)
2022
(14)
2024
(11)
2025
(7)
2023
(7)
2014
(5)
2011
(5)
2020
(4)
2016
(4)
2010
(4)
2026
(3)
2018
(3)
2013
(3)
2019
(2)
2015
(1)
2008
(1)
Previous
page
1 / 10
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
10
Next
page
Sort
by:
Relevance
Page size
10
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders.
Not available
S-EPMC10996091
|
biostudies-literature
Cite
Saving the World's Terrestrial Megafauna.
Not available
S-EPMC5421308
|
biostudies-literature
Cite
A localized view on molecular dissociation via electron-ion partial covariance.
Not available
S-EPMC9814695
|
biostudies-literature
Cite
Developmental Consequences of Defective ATG7-Mediated Autophagy in Humans.
Not available
S-EPMC7611730
|
biostudies-literature
Cite
Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.
Not available
S-EPMC4055488
|
biostudies-literature
Cite
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425
|
biostudies-literature
Cite
Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes.
Not available
S-EPMC3990173
|
biostudies-literature
Cite
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
Not available
S-EPMC3664945
|
biostudies-literature
Cite
The Type 2 Diabetes Knowledge Portal: An open access genetic resource dedicated to type 2 diabetes and related traits.
Not available
S-EPMC10231654
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Previous
page
1 / 10
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
10
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets